20Sep 2023
Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes

Albuminuria‐lowering effect of adding semaglutide on top of empagliflozin in individuals with type 2 diabetes

A study explored the impact of combining empagliflozin and semaglutide on urinary albumin-creatinine ratio (UACR) in type 2 diabetes (T2D) patients with albuminuria. In a randomized, placebo-controlled trial with 60 participants, empagliflozin was administered alongside renin-angiotensin system inhibition for 26 weeks, followed by randomization to semaglutide or placebo for 26 weeks. Results showed that semaglutide did not significantly alter UACR compared to empagliflozin alone. However, semaglutide led to improved glycemic control and reduced plasma aldosterone levels. The study suggests limited additional benefit in reducing UACR with combined treatment.

  • #endo-diabetology

Like

Save

Share